Trial Profile
A Multi-center, Randomized, Parallel-group, Rater-blinded Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis Plus a Long Term Extension Period
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Dec 2021
Price :
$35
*
At a glance
- Drugs Teriflunomide (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms TENERE
- Sponsors Sanofi
- 26 May 2020 Results of pooled analysis from TEMSO, TOWER, TENERE, TOPIC and TERI-PRO assessing lymphocyte levels in teriflunomide-treated patients stratified by age, presented at the 6th Congress of the European Academy of Neurology
- 06 May 2019 According to a Sanofi Genzyme media release, post-hoc analysis of four clinical studies: a Phase 2 study, Phase III TEMSO, TOWER and TENERE core studies and their extensions, will be presented during the 71st annual meeting of the American Academy of Neurology (AAN) in Philadelphia, PA.
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis